Syndax Pharmaceuticals (NASDAQ:SNDX) Posts Quarterly Earnings Results, Misses Expectations By $0.12 EPS

Syndax Pharmaceuticals (NASDAQ:SNDX) released its quarterly earnings data on Thursday. The company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.12), FiscalAI reports. Syndax Pharmaceuticals had a negative net margin of 279.31% and a negative return on equity of 160.60%. The business had revenue of $68.73 million for the quarter. During the same period in the prior year, the business earned ($1.10) EPS. The firm’s revenue was up 792.6% compared to the same quarter last year.

Here are the key takeaways from Syndax Pharmaceuticals’ conference call:

• Syndax reported strong commercial momentum for Revuforj, with $124.8M net revenue in 2025, a 38% sequential increase in Q4, ~35% prescription growth, and rapid uptake following the NPM1 label expansion.
• The Niktimvo launch outperformed benchmarks—$151.6M partner-reported net sales in 2025 (Syndax recorded $42.4M collaboration revenue) and high persistency, supporting expectations for growing margin contribution over time.
• Pipeline execution is advancing—pivotal frontline trials for revumenib (EVOLVE-2, REVEAL-ND, RAVEN) are enrolling and axatilimab completed Phase 2 enrollment in IPF (MAXPIRe) with top-line data expected in Q4 2026, creating multiple potential near- and mid-term value drivers.
• Financial position and guidance are solid, with total 2025 revenue of $172.4M, $394M in cash and equivalents, and 2026 R&D+SG&A guidance of ~ $400M (ex‑noncash stock comp), and management expects to reach profitability without raising additional capital.
• Key commercial assumptions remain uncertain—average Revuforj treatment duration was only ~4–6 months in year one and revenue growth depends on extended durations, higher post‑transplant restart rates, and broader combination/frontline uptake that may not materialize as projected.

Syndax Pharmaceuticals Price Performance

SNDX traded down $0.08 on Thursday, reaching $20.67. 1,358,353 shares of the company’s stock were exchanged, compared to its average volume of 1,129,768. The company has a debt-to-equity ratio of 2.78, a current ratio of 4.64 and a quick ratio of 4.42. The stock’s fifty day moving average price is $20.84 and its 200-day moving average price is $17.93. Syndax Pharmaceuticals has a twelve month low of $8.58 and a twelve month high of $22.73. The stock has a market cap of $1.80 billion, a PE ratio of -5.73 and a beta of 0.46.

Insider Buying and Selling at Syndax Pharmaceuticals

In other news, CEO Michael A. Metzger sold 17,159 shares of the firm’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $21.03, for a total transaction of $360,853.77. Following the completion of the sale, the chief executive officer owned 491,690 shares in the company, valued at $10,340,240.70. This trade represents a 3.37% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Keith A. Goldan sold 3,410 shares of the company’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $21.03, for a total value of $71,712.30. Following the completion of the transaction, the chief financial officer owned 140,429 shares in the company, valued at $2,953,221.87. This represents a 2.37% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 30,063 shares of company stock worth $628,332. Insiders own 4.10% of the company’s stock.

Hedge Funds Weigh In On Syndax Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of SNDX. Larson Financial Group LLC lifted its holdings in Syndax Pharmaceuticals by 192.2% during the 3rd quarter. Larson Financial Group LLC now owns 2,922 shares of the company’s stock worth $45,000 after buying an additional 1,922 shares during the last quarter. Quantbot Technologies LP acquired a new stake in shares of Syndax Pharmaceuticals during the 3rd quarter worth about $53,000. Smartleaf Asset Management LLC lifted its stake in Syndax Pharmaceuticals by 2,698.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 2,659 shares of the company’s stock worth $55,000 after purchasing an additional 2,564 shares during the last quarter. Lazard Asset Management LLC purchased a new stake in Syndax Pharmaceuticals during the second quarter worth approximately $66,000. Finally, Tower Research Capital LLC TRC boosted its holdings in Syndax Pharmaceuticals by 103.3% in the second quarter. Tower Research Capital LLC TRC now owns 8,480 shares of the company’s stock valued at $79,000 after purchasing an additional 4,308 shares in the last quarter.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. Barclays lifted their price target on Syndax Pharmaceuticals from $22.00 to $35.00 and gave the company an “overweight” rating in a report on Monday, November 24th. Wall Street Zen upgraded shares of Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, February 7th. UBS Group boosted their price target on Syndax Pharmaceuticals from $35.00 to $38.00 and gave the company a “buy” rating in a research note on Tuesday, November 4th. BTIG Research restated a “buy” rating and issued a $56.00 price objective on shares of Syndax Pharmaceuticals in a research note on Tuesday, December 9th. Finally, JPMorgan Chase & Co. decreased their target price on Syndax Pharmaceuticals from $40.00 to $33.00 and set an “overweight” rating for the company in a report on Wednesday, November 12th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Syndax Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $37.20.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax’s research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology.

The company’s lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications.